Compare Stocks: CYCN, ZYBT, SPRO, and LONA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CYCN Cyclerion Therapeutics	$3.49 +3.9%	$22.95	$1.03 ▼ $8.48	$16.33M	1.75	96,117 shs	435,914 shs
LONA Athira Pharma	$6.79 -2.3%	$7.63	$3.60 ▼ $14.21	$63.78M	2.05	40,282 shs	52,315 shs
SPRO Spero Therapeutics	$1.13 +0.9%	$1.26	$1.08 ▼ $3.08	$65.81M	1.49	327,356 shs	501,370 shs
ZYBT Zhengye Biotechnology	$1.37	$1.69	$0.62 ▼ $9.77	$64.93M	-2.56	52,773 shs	20,748 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CYCN Cyclerion Therapeutics	0.00%	0.00%	-87.93%	-84.42%	-78.60%
LONA Athira Pharma	-2.30%	-1.88%	-13.28%	-16.99%	+678,999,900.00%
SPRO Spero Therapeutics	+0.89%	0.00%	-8.13%	-50.44%	-40.53%
ZYBT Zhengye Biotechnology	0.00%	-11.61%	-25.95%	+82.67%	-85.65%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CYCN Cyclerion Therapeutics	$3.49 +3.9%	$22.95	$1.03 ▼ $8.48	$16.33M	1.75	96,117 shs	435,914 shs
LONA Athira Pharma	$6.79 -2.3%	$7.63	$3.60 ▼ $14.21	$63.78M	2.05	40,282 shs	52,315 shs
SPRO Spero Therapeutics	$1.13 +0.9%	$1.26	$1.08 ▼ $3.08	$65.81M	1.49	327,356 shs	501,370 shs
ZYBT Zhengye Biotechnology	$1.37	$1.69	$0.62 ▼ $9.77	$64.93M	-2.56	52,773 shs	20,748 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CYCN Cyclerion Therapeutics	0.00%	0.00%	-87.93%	-84.42%	-78.60%
LONA Athira Pharma	-2.30%	-1.88%	-13.28%	-16.99%	+678,999,900.00%
SPRO Spero Therapeutics	+0.89%	0.00%	-8.13%	-50.44%	-40.53%
ZYBT Zhengye Biotechnology	0.00%	-11.61%	-25.95%	+82.67%	-85.65%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CYCN Cyclerion Therapeutics	1.00	Sell	N/A	N/A
LONA Athira Pharma	2.50	Moderate Buy	$17.33	155.28% Upside
SPRO Spero Therapeutics	2.25	Hold	$6.00	430.97% Upside
ZYBT Zhengye Biotechnology	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest CYCN, ZYBT, SPRO, and LONA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/14/2026	SPRO Spero Therapeutics	Compass Point Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Neutral
9/14/2026	SPRO Spero Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold
9/14/2026	SPRO Spero Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$5.00 ➝ $6.00
8/19/2026	LONA Athira Pharma	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$16.00 ➝ $15.00
8/17/2026	LONA Athira Pharma	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Market Outperform	$18.00 ➝ $17.00
8/12/2026	SPRO Spero Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D-) ➝ Hold (C-)
8/7/2026	LONA Athira Pharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/30/2026	LONA Athira Pharma	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform	$18.00
7/24/2026	CYCN Cyclerion Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/20/2026	ZYBT Zhengye Biotechnology	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D-) ➝ Sell (D)
7/17/2026	SPRO Spero Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)

(Data available from 9/19/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CYCN Cyclerion Therapeutics	$2.07M	7.89	N/A	N/A	$2.31 per share	1.51
LONA Athira Pharma	N/A	N/A	N/A	N/A	$2.98 per share	N/A
SPRO Spero Therapeutics	$66.80M	0.99	$0.15 per share	7.43	$1.05 per share	1.08
ZYBT Zhengye Biotechnology	$16.64M	3.90	N/A	N/A	$0.93 per share	1.47

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CYCN Cyclerion Therapeutics	-$3.53M	-$1.66	N/A	N/A	N/A	-170.11%	-87.96%	-74.86%	11/11/2026 (Estimated)
LONA Athira Pharma	-$105.61M	-$4.21	N/A	N/A	N/A	N/A	-411.58%	-225.73%	N/A
SPRO Spero Therapeutics	$8.57M	$0.11	10.27	N/A	N/A	24.90%	16.17%	12.57%	11/12/2026 (Estimated)
ZYBT Zhengye Biotechnology	-$9.98M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Latest CYCN, ZYBT, SPRO, and LONA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/14/2026	Q2 2026	LONA Athira Pharma	-$0.60	-$0.80	-$0.20	-$0.80	N/A	N/A
8/12/2026	Q2 2026	SPRO Spero Therapeutics	-$0.17	-$0.16	+$0.01	-$0.16	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CYCN Cyclerion Therapeutics	N/A	N/A	N/A	N/A	N/A
LONA Athira Pharma	N/A	N/A	N/A	N/A	N/A
SPRO Spero Therapeutics	N/A	N/A	N/A	N/A	N/A
ZYBT Zhengye Biotechnology	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CYCN Cyclerion Therapeutics	N/A	0.82	0.82
LONA Athira Pharma	N/A	7.01	7.01
SPRO Spero Therapeutics	N/A	6.12	6.12
ZYBT Zhengye Biotechnology	0.03	1.14	0.82

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CYCN Cyclerion Therapeutics	75.62%
LONA Athira Pharma	57.12%
SPRO Spero Therapeutics	25.60%
ZYBT Zhengye Biotechnology	N/A

Insider Ownership

Company	Insider Ownership
CYCN Cyclerion Therapeutics	34.30%
LONA Athira Pharma	25.73%
SPRO Spero Therapeutics	2.90%
ZYBT Zhengye Biotechnology	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CYCN Cyclerion Therapeutics	30	4.68 million	3.08 million	No Data
LONA Athira Pharma	19	9.39 million	6.98 million	No Data
SPRO Spero Therapeutics	150	58.24 million	56.55 million	Optionable
ZYBT Zhengye Biotechnology	269	47.39 million	N/A	N/A

CYCN, ZYBT, SPRO, and LONA Headlines

Recent News About These Companies

Zhengye Biotechnology Holding Ltd (ZYBT)

August 28, 2026 | ru.investing.com

Zhengye Biotechnology Regains Nasdaq Minimum Bid Price Compliance

August 6, 2026 | tipranks.com

Why Zhengye Biotechnology Holding (ZYBT) Stock Is Up Today

August 5, 2026 | quiverquant.comQ

Zhengye Biotechnology Stock Short Interest Report | NASDAQ:ZYBT | Benzinga

July 23, 2026 | benzinga.com

Zhengye Biotechnology Addresses Unusual Nasdaq Trading Activity

July 21, 2026 | tipranks.com

Zhengye Biotechnology says no material events behind unusual trading activity (NASDAQ: ZYBT)

July 21, 2026 | msn.com

Zhengye Biotechnology Holding Limited Says It Is Unaware of Material Non-Public Information Amid Unusual Trading Activity

July 21, 2026 | quiverquant.comQ

Zhengye Biotechnology Holding Limited Comments on Unusual Trading Activity

July 21, 2026 | globenewswire.com

Why Zhengye Biotechnology Holding Limited (ZYBT) Stock Is Up Today

July 20, 2026 | quiverquant.comQ

Zhengye Biotechnology Holding Ltd. Class A

July 13, 2026 | cnn.com

Zhengye Biotechnology Faces Nasdaq Minimum Bid Price Deficiency After May 29 Notice

June 4, 2026 | tipranks.com

Zhengye Biotechnology Holding Limited Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

June 4, 2026 | globenewswire.com

Zhengye Biotechnology Holding Limited Announces Fiscal Year 2025 Financial Results

April 28, 2026 | prnewswire.com

Zhengye Biotechnology Holding Limited Announces Implementation of Dual-Class Share Structure Effective April 7, 2026

April 6, 2026 | quiverquant.comQ

Zhengye Biotechnology Holding Limited Announces Implementation of Dual-Class Share Structure

April 6, 2026 | globenewswire.com

Zhengye Biotechnology Holding Ltd ZYBT

March 28, 2026 | morningstar.comM

Zhengye Biotechnology Shareholders Approve Governance and Share Structure Changes at March 24 AGM

March 25, 2026 | tipranks.com

Zhengye Biotechnology Director Resigns, Nasdaq Independence Deficiency to Be Addressed at March AGM

February 23, 2026 | tipranks.com

Zhengye Biotechnology Holding Limited Issues 2026 Chairman’s Letter to Shareholders

February 11, 2026 | markets.businessinsider.com

Zhengye Biotechnology Holding Limited Highlights 2025 Achievements and 2026 Strategic Plan in Shareholder Letter

February 10, 2026 | quiverquant.comQ

New MarketBeat Followers Over Time

Media Sentiment Over Time

CYCN, ZYBT, SPRO, and LONA Company Descriptions

Cyclerion Therapeutics NASDAQ:CYCN

$3.49 +0.13 (+3.87%)

Closing price 09/8/2026

Extended Trading

$3.49 0.00 (0.00%)

As of 09/8/2026 07:42 PM Eastern

Cyclerion Therapeutics, Inc., a biopharmaceutical company, develops treatments for serious diseases. It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to out-license for cardiovascular diseases; and Praliciguat, a systemic sGC stimulator that is licensed to Akebia Therapeutics, Inc. for the treatment of rare kidney disease. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

Athira Pharma NASDAQ:LONA

$6.79 -0.16 (-2.30%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$6.67 -0.12 (-1.83%)

As of 09/18/2026 04:17 PM Eastern

Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is Fosgonimeton (ATH-1017), a small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease dementia and Dementia with Lewy bodies. The company's product pipeline includes ATH-1020, an orally available brain-penetrant small molecule designed to enhance the HGF/MET system that is in Phase 1 clinical trials to treat neuropathic pain and neurodegenerative diseases; and ATH-1105, an oral small molecule drug candidate, which is a preclinical model for the treatment of Amyotrophic Lateral Sclerosis. In addition, it has a license agreement with Washington State University to offer for sale products covered by certain licensed patents, including dihexa, the chemical compound into which fosgonimeton metabolizes following administration; and collaboration and grant agreement with National Institutes of Health Grant to support ACT-AD Phase 2 clinical trial for fosgonimeton. The company was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. Athira Pharma, Inc. was incorporated in 2011 and is headquartered in Bothell, Washington.

Spero Therapeutics NASDAQ:SPRO

$1.13 +0.01 (+0.89%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$1.12 0.00 (-0.44%)

As of 09/18/2026 07:30 PM Eastern

Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; and Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. Spero Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Zhengye Biotechnology NASDAQ:ZYBT

$1.37 0.00 (0.00%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$1.32 -0.05 (-3.28%)

As of 09/18/2026 07:56 PM Eastern

Zhengye Biotechnology Holding Limited is a veterinary vaccine manufacturer which encompasses research, development, manufacturing and sales of veterinary vaccines, with a focus on livestock vaccine principally in China. Zhengye Biotechnology Holding Limited is based in Jilin, China.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CYCN, ZYBT, SPRO, and LONA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CYCN, ZYBT, SPRO, and LONA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CYCN, ZYBT, SPRO, and LONA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CYCN, ZYBT, SPRO, and LONA Company Descriptions

Cyclerion Therapeutics NASDAQ:CYCN

Athira Pharma NASDAQ:LONA

Spero Therapeutics NASDAQ:SPRO

Zhengye Biotechnology NASDAQ:ZYBT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CYCN, ZYBT, SPRO, and LONA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CYCN, ZYBT, SPRO, and LONA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CYCN, ZYBT, SPRO, and LONA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CYCN, ZYBT, SPRO, and LONA Company Descriptions

Cyclerion Therapeutics NASDAQ:CYCN

Athira Pharma NASDAQ:LONA

Spero Therapeutics NASDAQ:SPRO

Zhengye Biotechnology NASDAQ:ZYBT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools